- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/46 - Hybrid immunoglobulins
Patent holdings for IPC class C07K 16/46
Total number of patents in this class: 7965
10-year publication summary
|
507
|
584
|
658
|
650
|
626
|
682
|
686
|
604
|
533
|
393
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4790 |
257 |
| Hoffmann-La Roche Inc. | 3825 |
183 |
| F. Hoffmann-La Roche AG | 7800 |
174 |
| Chugai Seiyaku Kabushiki Kaisha | 1422 |
150 |
| Amgen Inc. | 4436 |
143 |
| Genentech, Inc. | 4119 |
115 |
| Xencor, Inc. | 411 |
115 |
| Janssen Biotech, Inc. | 1785 |
90 |
| Zymeworks Inc. | 258 |
76 |
| The Regents of the University of California | 20842 |
71 |
| Kymab Limited | 280 |
71 |
| Amgen Research (Munich) GmbH | 260 |
64 |
| Merus N.V. | 191 |
63 |
| Sanofi | 4322 |
59 |
| Ablynx N.V. | 424 |
58 |
| Novartis AG | 10175 |
56 |
| Genmab A/S | 476 |
51 |
| Daiichi Sankyo Company, Limited | 1891 |
48 |
| MacroGenics, Inc. | 232 |
47 |
| National Research Council of Canada | 1549 |
47 |
| Other owners | 6027 |